Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neo-adjuvant treatment in patients with operable Triple Negative or luminal B/HER2 normal Breast Cancer

Next Previous
X
Search
Trial Profile

Randomized, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neo-adjuvant treatment in patients with operable Triple Negative or luminal B/HER2 normal Breast Cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 19 Oct 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cabazitaxel (Primary) ; Cyclophosphamide; Epirubicin; Paclitaxel
  • Indications Advanced breast cancer; Early breast cancer; HER2 negative breast cancer; Triple negative breast cancer
  • Focus Therapeutic Use
  • Acronyms GENEVIEVE

    • Most Recent Events

    • 13 Sep 2022 Long term survival results assessing the efficacy and safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer presented at the 47th European Society for Medical Oncology Congress.
    • 30 Jul 2017 The protocol has amended for epirubicin and cyclophosphamide treatment sequence to taxane during recruitment because of low recruitment and in case of TNBC monotherapy prior to surgery was not accepted, according to results published in the European Journal of Cancer
    • 30 Jul 2017 Results published in the European Journal of Cancer

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top